Bristol Myers Squibb (BMY) Change in Cash (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Change in Cash for 18 consecutive years, with -$861.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Change in Cash fell 149.6% year-over-year to -$861.0 million in Q2 2026; TTM through Jun 2026 was -$3.9 billion, a 161.58% decrease from a year earlier, with the FY2025 full-year figure at -$129.0 million, up 88.99% from the prior year.
• Change in Cash was -$861.0 million for Q2 2026 at Bristol Myers Squibb, down from -$635.0 million in the prior quarter.
• Over five years, Change in Cash peaked at $4.0 billion in Q4 2023 and troughed at -$5.5 billion in Q4 2025.
• A 5-year average of -$310.8 million and a median of -$629.0 million in 2023 frame the typical range for Change in Cash.
• Across the five-year window, Change in Cash slumped 2230.26% in 2022 and jumped 286.35% in 2024, its largest moves.
• Over 5 years, Change in Cash stood at $1.4 billion in 2022, then soared by 188.82% to $4.0 billion in 2023, then plunged by 37.89% to $2.5 billion in 2024, then plunged by 324.45% to -$5.5 billion in 2025, then surged by 84.37% to -$861.0 million in 2026.
• The last three Change in Cash figures came in at -$861.0 million (Q2 2026), -$635.0 million (Q1 2026), and -$5.5 billion (Q4 2025), per Business Quant data.